Danaher nears $10 billion acquisition of Masimo: FT reports

• The deal is valued at nearly $10 billion, making it a significant healthcare sector acquisition
• Danaher is a US-based healthcare manufacturer looking to expand its medical technology portfolio
• The report comes from unnamed sources and has not been officially confirmed by either company

Summary: Danaher Nears $10 Billion Masimo Acquisition

Key Transaction Details:

U.S. healthcare manufacturer Danaher is approaching a nearly $10 billion deal to acquire Masimo, a medical technology company, according to a Financial Times report citing sources familiar with the matter. Reuters has not independently verified this information.

Companies Involved:

• Danaher: A major U.S. healthcare manufacturing company and the acquiring entity
• Masimo: A medical technology firm positioned as the acquisition target

Deal Value:

The transaction is valued at approximately $10 billion, representing a significant consolidation move in the healthcare technology sector.

Market Implications:

This potential mega-deal signals continued M&A activity in the healthcare and medical technology space, where larger manufacturers are seeking to expand their portfolios and technological capabilities. If completed, this would rank among the larger healthcare sector acquisitions in recent years.

The acquisition would strengthen Danaher's position in medical technology and could provide synergies in product development, distribution, and market reach. For Masimo shareholders, the deal represents a potential premium valuation and exit opportunity.

Current Status:

Negotiations are reportedly in advanced stages ("closing in"), though no final agreement has been announced. The deal terms, financing structure, and regulatory approval timeline remain undisclosed.

Important Note:

As this information comes from unnamed sources and lacks independent verification, investors should await official confirmation from either company before making investment decisions. Both companies have not yet issued public statements regarding the reported transaction.